Leukocyte protein tyrosine kinases: potential targets for drug discovery
- PMID: 9143693
- DOI: 10.1146/annurev.immunol.15.1.371
Leukocyte protein tyrosine kinases: potential targets for drug discovery
Abstract
Intracellular signal transduction following the extracellular ligation of a wide variety of different types of surface molecules on leukocytes involves the activation of protein tyrosine kinases. The dependence of successful intracellular signaling on the functions of the nontransmembrane class of protein tyrosine kinases coupled with the cell type-specific expression patterns for several of these enzymes makes them appealing targets for therapeutic intervention. Development of drugs that can interfere with the catalytic functions of the nontransmembrane protein tyrosine kinases or that can disrupt critical interactions with regulatory molecules and/or substrates should find clinical applications in the treatment of allergic diseases, autoimmunity, transplantation rejection, and cancer.
Similar articles
-
Protein tyrosine kinases: structure, substrate specificity, and drug discovery.Biopolymers. 1998;47(3):197-223. doi: 10.1002/(SICI)1097-0282(1998)47:3<197::AID-BIP2>3.0.CO;2-H. Biopolymers. 1998. PMID: 9817025 Review.
-
Redox control of catalytic activities of membrane-associated protein tyrosine kinases.Arch Biochem Biophys. 2005 Feb 1;434(1):3-10. doi: 10.1016/j.abb.2004.06.016. Arch Biochem Biophys. 2005. PMID: 15629102 Review.
-
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review.
-
Src homology-2 domains: structure, mechanisms, and drug discovery.Biopolymers. 1998;47(3):243-61. doi: 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P. Biopolymers. 1998. PMID: 9817027 Review.
-
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.Circulation. 2004 Mar 16;109(10):1196-205. doi: 10.1161/01.CIR.0000118538.21306.A9. Circulation. 2004. PMID: 15023894 Review.
Cited by
-
Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.Drug Des Devel Ther. 2022 Apr 2;16:991-998. doi: 10.2147/DDDT.S353494. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35400994 Free PMC article. Review.
-
Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement.Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9611-6. doi: 10.1073/pnas.161298098. Epub 2001 Aug 7. Proc Natl Acad Sci U S A. 2001. PMID: 11493682 Free PMC article.
-
Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase.PLoS One. 2016 Jan 5;11(1):e0145872. doi: 10.1371/journal.pone.0145872. eCollection 2016. PLoS One. 2016. PMID: 26731115 Free PMC article.
-
JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells.Mol Endocrinol. 2008 Aug;22(8):1825-41. doi: 10.1210/me.2008-0015. Epub 2008 May 22. Mol Endocrinol. 2008. PMID: 18499741 Free PMC article.
-
Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain.Biochem J. 2003 May 15;372(Pt 1):271-8. doi: 10.1042/BJ20030021. Biochem J. 2003. PMID: 12600271 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
